Iltar, U. Et Al. 2023. Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib. UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4 , 191-197.

Iltar, U., Salim, O., Ataş, Ü., Vural, E., Alhan, F. N., Yücel, O. K., ... Sözel, H.(2023). Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib. UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, 191-197.

Iltar, UTKU Et Al. "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib," UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, 191-197, 2023

Iltar, UTKU Et Al. "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib." UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, pp.191-197, 2023

Iltar, U. Et Al. (2023) . "Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib." UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.33, no.4, pp.191-197.

@article{article, author={UTKU ILTAR Et Al. }, title={Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib}, journal={UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI}, year=2023, pages={191-197} }